Related Experiment Videos
Systemic chemotherapy for muscle invasive bladder cancer
1Department of Urology, Comenius University School of Medicine, Dérer Hospital, Bratislava, Slovakia.
Neoplasma
|January 1, 1994
Summary
Neoadjuvant chemotherapy for muscle-invasive bladder cancer shows promise. M-VAC and CMV regimens offer clinical responses, but radical cystectomy is recommended for optimal outcomes in eligible patients.
Area of Science:
- Urology
- Oncology
- Medical Oncology
Background:
- Muscle-invasive bladder cancer (MIBC) requires effective treatment strategies.
- Neoadjuvant chemotherapy is a key component in managing MIBC.
Purpose of the Study:
- To compare the efficacy of two neoadjuvant chemotherapy regimens (M-VAC and CMV) for MIBC.
- To evaluate clinical and pathological response rates and survival outcomes.
Main Methods:
- A non-randomized study involving 60 patients with MIBC.
- Group 1 received M-VAC chemotherapy followed by radical cystectomy.
- Group 2 received CMV (carboplatin) chemotherapy followed by radical cystectomy.
Main Results:
- M-VAC group: 70% overall clinical response, 50% clinical complete response (cCR), 22.2% pathologic complete response (pCR) in evaluable patients, 33.3% survival at 22+ months.
- CMV group: Higher survival rate (80% at 13+ months), 47.4% objective pathologic response, 31.6% pCR in evaluable patients.
- Drug-related deaths occurred in 10% (M-VAC) and 3.3% (CMV) of patients.
Conclusions:
- Both M-VAC and CMV neoadjuvant chemotherapy regimens show activity in MIBC.
- The study recommends immediate radical cystectomy post-chemotherapy for eligible patients.
- Further research may explore optimizing neoadjuvant strategies for improved outcomes.